Document ID: chunk:federal_register_of_legislation:F2024L01390:schedule:1
Version: federal_register_of_legislation:F2024L01390
Segment Type: schedule
Provision Reference: sch 1
Character Range: 2182–4978

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

     1.            Schedule 1, after entry for Dapagliflozin with metformin in the form Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride
         insert:
Dapagliflozin with sitagliptin  Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate)  20  28  5

     1.            Schedule 1, entry for Estradiol
         substitute:
Estradiol                                                Tablet 2 mg  20  56  2
Tablet containing estradiol valerate 1 mg                20           56  2
Tablet containing estradiol valerate 2 mg                20           56  2
Transdermal gel 500 micrograms in 0.5 g sachet, 28       20           1   5
Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28  20           1   5
Transdermal patches 390 micrograms, 8                    20           1   5
Transdermal patches 585 micrograms, 8                    20           1   5
Transdermal patches 585 micrograms, 24 (S19A)            20           1   1
Transdermal patches 750 micrograms (as hemihydrate), 8   20           1   5
Transdermal patches 780 micrograms, 8                    20           1   5
Transdermal patches 780 micrograms, 24 (S19A)            20           1   1
Transdermal patches 1.17 mg, 8                           20           1   5
Transdermal patches 1.17 mg, 24 (S19A)                   20           1   1
Transdermal patches 1.5 mg (as hemihydrate), 8           20           1   5
Transdermal patches 1.56 mg, 8                           20           1   5
Transdermal patches 1.56 mg, 24 (S19A)                   20           1   1
Transdermal patches 3 mg (as hemihydrate), 8             20           1   5

     1.            Schedule 1, after entry for Methotrexate in the form Injection 25 mg in 0.5 mL pre-filled syringe
         insert:
   Tablet 10 mg  20  10  5

     1.            Schedule 1, omit entry for Ribavirin
     2.            Schedule 1, entry for Risankizumab
         omit:
   Injection 75 mg in 0.83 mL pre‑filled syringe  20  2  1

     1.            Schedule 2, after entry for Dapagliflozin with metformin in the form Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride
         insert:
Dapagliflozin with sitagliptin  Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate)  50  56  5

     1.            Schedule 2, after entry Estradiol in the form Tablet containing estradiol valerate 2 mg
         insert:
   Transdermal gel 500 micrograms in 0.5 g sachet, 28  50  2  5